Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fidthera
- Ownership
- Private
- Development stage
- Other
01
Overview
Fidthera is a biotechnology company focused on developing next-generation cell therapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary platform to engineer T cells with enhanced specificity and durability, aiming to overcome the limitations of current adoptive cell transfer approaches. By focusing on novel T cell receptor (TCR) discovery and optimization, Fidthera seeks to provide more effective and safer therapeutic options for patients with high unmet medical needs. The company's pipeline is currently in the pre-clinical stage, with multiple programs targeting various solid tumors and inflammatory conditions.
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Cell therapyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Fidthera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fidthera.